Non-viral episomal vectors for primate stem cell reprogramming
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating induced pluripotent stem cells (iPS cells) using retroviral vectors pose risks due to untargeted integration into the genome, potential aberrant gene expression, and neoplastic growth, as well as interference with cellular physiology and differentiation.
Innovation Solution
The method involves introducing non-viral episomal vectors encoding potency-determining factors like OCT4, SOX2, and c-Myc into somatic cells to reprogram them into pluripotent cells, ensuring the vectors are transient and largely absent from the reprogrammed cells, reducing genetic alteration and vector-related risks.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If retroviral vectors are used to deliver transcription factors into somatic cells, then reprogramming efficiency is improved, but genomic safety deteriorates due to untargeted integration and potential neoplastic growth
Solution Approach 1:
The patent extracts the harmful integration function from the retroviral vector system and replaces it with non-integrating alternatives such as episomal vectors, mRNA transfection, or protein transduction. This removes the source of genomic damage while preserving the essential reprogramming function of delivering transcription factors (OCT4, SOX2, c-MYC, KLF4) into somatic cells to induce pluripotency.
Solution Approach 2:
The patent employs transient delivery methods where the reprogramming factors are introduced temporarily and then eliminated. Episomal vectors are lost during cell division, mRNA degrades naturally, and proteins have limited half-lives. This ensures that the reprogramming stimulus is sufficient to induce pluripotency but does not persist to cause long-term genomic harm or interfere with subsequent cell differentiation.
2Productivity
If transcription factors are continuously expressed during reprogramming, then reprogramming efficiency is improved, but cellular physiology deteriorates due to interference with normal cell function and differentiation
Solution Approach 1:
The patent implements periodic or transient expression of transcription factors rather than continuous expression.通过使用 episomal vectors that are gradually lost during cell division, mRNA that degrades over time, or proteins with limited stability, the reprogramming stimulus is delivered in a controlled temporal manner. This allows sufficient expression to drive reprogramming while avoiding prolonged interference with cellular physiology and subsequent differentiation processes.
3Productivity
If viral vectors are used for reprogramming, then delivery efficiency is improved, but immune rejection risk increases due to viral components
Solution Approach 1:
The patent removes the viral vector system entirely and replaces it with non-viral delivery methods including episomal plasmids, synthetic mRNA, or purified proteins. This extraction eliminates viral components that could trigger immune responses while maintaining the ability to deliver reprogramming factors efficiently. The non-viral approaches avoid activation of innate immune sensors and reduce the risk of adaptive immune rejection.
Data Source
AI summary
Methods for reprogramming primate somatic cells to pluripotency using an episomal vector that does not encode an infectious virus are disclosed. Pluripotent cells produced in the methods are also disclosed.